Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Astraea Therapeutics General Information
Astraea Therapeutics has advanced its lead candidate(s) into Phase I clinical trials for smoking cessation. Preclinical data support efficacy in preventing relapse triggered by stress or cues and suggest potential application across multiple substance addictions. Additional programs are at the preclinical stage targeting pain management without typical opioid side effects and alcohol use disorder.
Contact Information
Primary Industry
Biotech
Corporate Office
Mountain View / Saratoga*, California
United States
United States
Drug Pipeline
AT-121
Phase 1Key Partnerships
Astraea Therapeutics Funding
No funding data available
To view Astraea Therapeutics's complete valuation and funding history, request access »